The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells

J Asano, A Nakano, A Oda, H Amou, M Hiasa… - Leukemia, 2011 - nature.com
Bone marrow stromal cells (BMSCs) and osteoclasts (OCs) confer multiple myeloma (MM)
cell survival through elaborating factors. We demonstrate herein that IL-6 and TNF family …

[HTML][HTML] Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells

A Nakano, D Tsuji, H Miki, Q Cui, SME Sayed… - PloS one, 2011 - journals.plos.org
Cancer cells eventually acquire drug resistance largely via the aberrant expression of ATP-
binding cassette (ABC) transporters, ATP-dependent efflux pumps. Because cancer cells …

Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma

M Hiasa, J Teramachi, A Oda, R Amachi, T Harada… - Leukemia, 2015 - nature.com
Pim-2 kinase is overexpressed in multiple myeloma (MM) cells to enhance their growth and
survival, and regarded as a novel therapeutic target in MM. However, the impact of Pim-2 …

Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate

A Nakano, H Miki, S Nakamura, T Harada… - Journal of bioenergetics …, 2012 - Springer
Abstracts Hexokinase II (HKII), a key enzyme of glycolysis, is widely over-expressed in
cancer cells. However, HKII levels and its roles in ATP production and ATP-dependent …

[HTML][HTML] TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma

J Teramachi, H Tenshin, M Hiasa, A Oda… - …, 2021 - ncbi.nlm.nih.gov
Along with tumor progression, the bone marrow microenvironment is skewed in multiple
myeloma (MM), which underlies the unique pathophysiology of MM and confers …

Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma

S Ozaki, O Tanaka, S Fujii, Y Shigekiyo, H Miki… - International journal of …, 2007 - Springer
Bortezomib is a novel proteasome inhibitor that has shown marked antitumor effects in
patients with multiple myeloma (MM). We evaluated the feasibility and efficacy of bortezomib …

Comparison and analysis of delirium induced by histamine H2 receptor antagonists and proton pump inhibitors in cancer patients

S Fujii, H Tanimukai, Y Kashiwagi - Case Reports in Oncology, 2012 - karger.com
Objective: H2 blockers have been reported to be responsible for drug-induced delirium. We
compared the incidence of delirium between two groups of patients who were treated with …

Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome

S Nakamura, M Azuma, T Maruhashi, K Sogabe… - Journal of infection and …, 2018 - Elsevier
Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne infectious disease
caused by the SFTS virus (SFTSV). Clinical symptoms of SFTS often involve …

[HTML][HTML] The roles of ROS generation in RANKL-induced osteoclastogenesis: Suppressive effects of febuxostat

M Ashtar, H Tenshin, J Teramachi, A Bat-Erdene… - Cancers, 2020 - mdpi.com
Receptor activator of NF-κB ligand (RANKL), a critical mediator of osteoclastogenesis, is
upregulated in multiple myeloma (MM). The xanthine oxidase inhibitor febuxostat, clinically …

Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan

M Yanada, A Takami, S Mizuno, J Mori, T Chou… - International journal of …, 2020 - Springer
Autologous hematopoietic cell transplantation (HCT) has not gained universal popularity in
the treatment of acute myeloid leukemia (AML), and its status remains unclear. To determine …